Santhera Receives Approval for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy in the United Kingdom

AGAMREE (Vamorolone), whose development at ReveraGen Biopharma was supported by CureDuchenne, has been approved in the United Kingdom (UK) for individuals with Duchenne aged 4 years and older. The Medicines Healthcare products Regulatory Agency (MHRA) recognized not just the efficacy of AGAMREE, but also clinical benefits with regards to preserving bone health and maintaining growth compared to standard corticosteroids. Santhera Pharmaceuticals is planning on having AGAMREE available in the UK in the second half of 2024.  AGAMREE was also approved in the US and in Europe in 2023. 

READ THE FULL NEWS RELEASE HERE